openPR Logo
Press release

Investigation announced for Long-Term Investors in Provention Bio, Inc. (NASDAQ: PRVB) shares

09-15-2021 08:11 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares.

An investigation on behalf of current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Provention Bio, Inc..

Investors who are current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: PRVB stocks follows a lawsuit filed against Provention Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PRVB stocks, concerns whether certain Provention Bio, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that the teplizumab BLA was deficient in its submitted form and would require additional data to secure FDA approval, that accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed, that the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Provention Bio, Inc. (NASDAQ: PRVB) shares here

News-ID: 2394820 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Provention

Bispecific Antibody Competitive Landscape Report 2025 | Janssen, Amgen, Akeso, Z …
DelveInsight's, "Bispecific antibody - Competitive landscape, 2025," report provides comprehensive insights about 180+ companies and 250+ drugs in Bispecific antibody Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Bispecific Antibody Competitive Landscape Report • DelveInsight's Bispecific Antibody report depicts a robust space with 180+ active players working to develop 250+
Gluten Sensitivity Market to Rise by 2032 | 9 Meters Biopharma, ImmunogenX, Prov …
DelveInsight's "Gluten Sensitivity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gluten Sensitivity, historical and forecasted epidemiology as well as the Gluten Sensitivity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Gluten Sensitivity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gluten Sensitivity market size
Bispecific Antibody Competitive Landscape Report 2024 (Updated) | Janssen, Amgen …
DelveInsight's, "Bispecific antibody Competitive landscape 2024" report provides comprehensive insights about 250+ Bispecific Antibody companies and 300+ Bispecific Antibody drugs in Bispecific antibody Competitive landscape. It covers the Bispecific Antibody therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Bispecific Antibody Competitive Landscape Report • DelveInsight's Bispecific Antibody report depicts a robust space with 250+
Bispecific Antibody Competitive Landscape Report (Updated) | Janssen, Amgen, Ake …
DelveInsight's, "Bispecific antibody Competitive landscape" report provides comprehensive insights about 250+ Bispecific Antibody companies and 300+ Bispecific Antibody drugs in Bispecific antibody Competitive landscape. It covers the Bispecific Antibody therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Bispecific Antibody Competitive Landscape Report • DelveInsight's Bispecific Antibody report depicts a robust space with 250+ active
Gluten Sensitivity Market to Witness Growth by 2032 | 9 Meters Biopharma, Immuno …
DelveInsight's "Gluten Sensitivity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gluten Sensitivity, historical and forecasted epidemiology as well as the Gluten Sensitivity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Gluten Sensitivity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gluten Sensitivity market size
Deadline on July 20th coming up ion Lawsuit for Investors in Provention Bio, Inc …
A deadline is coming up on July 20, 2021 in the lawsuit filed for certain investors of Provention Bio, Inc. (NASDAQ: PRVB) over alleged securities laws violations by Provention Bio, Inc. Investors who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB) have certain options and there are strict and short deadlines running. Deadline: July 20, 2021. NASDAQ: PRVB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -